Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 4, pp 897–914 | Cite as

Acute and Acute Severe (Fulminant) Autoimmune Hepatitis

  • Albert J. Czaja
Review

Abstract

Autoimmune hepatitis frequently has an abrupt onset of symptoms, and it can present with acute liver failure. The abrupt presentation can indicate spontaneous exacerbation of a pre-existent chronic disease, newly created disease, a superimposed infectious or toxic injury, or new disease after viral infection, drug therapy, or liver transplantation. Deficiencies in the classical phenotype may include a low serum immunoglobulin G level and low or absent titers of the conventional autoantibodies. The original revised diagnostic scoring system of the International Autoimmune Hepatitis Group can guide the diagnostic evaluation, but low scores do not preclude the diagnosis. Liver tissue examination is valuable to exclude viral-related or drug-induced liver injury and support the diagnosis by demonstrating centrilobular necrosis (usually with interface hepatitis), lymphoplasmacytic infiltration, hepatocyte rosettes, and fibrosis. Conventional therapy with prednisone and azathioprine induces clinical and laboratory improvement in 68–75 % of patients with acute presentations, and high dose prednisone or prednisolone (preferred drug) is effective in 20–100 % of patients with acute severe (fulminant) presentations. Failure to improve or worsening of any clinical or laboratory feature within 2 weeks of treatment or worsening of a mathematical model of end-stage liver disease within 7 days justifies liver transplantation in acute liver failure. Liver transplantation for acute severe (fulminant) autoimmune hepatitis is as successful as liver transplantation for autoimmune hepatitis with a chronic presentation and other types of acute liver failure (patient survival >1 year, 80–94 %). Liver transplantation should not be delayed or superseded by protracted corticosteroid therapy or the empiric institution of nonstandard medications.

Keywords

Acute Acute severe Fulminant Autoimmune Diagnosis Outcome Treatment 

Notes

Conflict of interest

None.

References

  1. 1.
    Crapper RM, Bhathal PS, Mackay IR, Frazer IH. “Acute” autoimmune hepatitis. Digestion. 1986;34:216–225.PubMedCrossRefGoogle Scholar
  2. 2.
    Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol. 1989;11:303–307.PubMedCrossRefGoogle Scholar
  3. 3.
    Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871.PubMedCrossRefGoogle Scholar
  4. 4.
    Michalska Z, Radowska D, Staike P, et al. Autoimmune hepatitis in the material of Department and Regional Hospital of Infectious Diseases in Gdansk. Med Sci Monit. 2003;9:49–54.PubMedGoogle Scholar
  5. 5.
    Ferrari R, Pappas G, Agostinelli D, et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the “acute” type. QJM. 2004;97:407–412.PubMedCrossRefGoogle Scholar
  6. 6.
    Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr. 1990;11:138–140.PubMedCrossRefGoogle Scholar
  7. 7.
    Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol. 1997;27:578–582.PubMedCrossRefGoogle Scholar
  8. 8.
    Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J. 1998;17:297–300.PubMedGoogle Scholar
  9. 9.
    Aydogdu S, Ozgenc F, Yurtsever S, et al. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J Trop Pediatr. 2003;49:367–370.PubMedCrossRefGoogle Scholar
  10. 10.
    Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631.PubMedCrossRefGoogle Scholar
  11. 11.
    Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006;23:1347–1353.PubMedCrossRefGoogle Scholar
  12. 12.
    Mudawi HM, Yousif BA. Fulminant hepatic failure in an African setting: etiology, clinical course, and predictors of mortality. Dig Dis Sci. 2007;52:3266–3269.PubMedCrossRefGoogle Scholar
  13. 13.
    Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–390.PubMedCrossRefGoogle Scholar
  14. 14.
    Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res. 2011;41:133–141.PubMedCrossRefGoogle Scholar
  15. 15.
    Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol. 2011;26:65–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res. 2011;41:498–504.PubMedCrossRefGoogle Scholar
  17. 17.
    Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–861.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic hepatitis. Am J Dig Dis. 1973;18:177–184.PubMedCrossRefGoogle Scholar
  19. 19.
    Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc. 1982;57:303–309.PubMedGoogle Scholar
  20. 20.
    Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003.PubMedCrossRefGoogle Scholar
  21. 21.
    Takikawa Y, Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. Hepatol Res. 2008;38:S14–S18.PubMedCrossRefGoogle Scholar
  22. 22.
    Fujiwara K, Mochida S, Matsui A, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–657.PubMedCrossRefGoogle Scholar
  23. 23.
    Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53:517–526.PubMedCrossRefGoogle Scholar
  24. 24.
    Magrin S, Craxi A, Fiorentino G, et al. Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol. 1991;13:56–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993;18:342–352.PubMedCrossRefGoogle Scholar
  26. 26.
    Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology. 1977;72:1348–1353.PubMedGoogle Scholar
  27. 27.
    Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis. 1981;1:104–115.PubMedCrossRefGoogle Scholar
  28. 28.
    Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–976.PubMedCrossRefGoogle Scholar
  29. 29.
    Czaja AJ. Current problems in the diagnosis and management of chronic active hepatitis. Mayo Clin Proc. 1981;56:311–323.PubMedGoogle Scholar
  30. 30.
    Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology. 2000;31:1194–1200.PubMedCrossRefGoogle Scholar
  31. 31.
    Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207–215.PubMedCrossRefGoogle Scholar
  32. 32.
    Leevy CM, Popper H, Sherlock S. Hepatitis. Fogarty Int Proc. 1976;22:1–11.Google Scholar
  33. 33.
    De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet. 1968;2:626–628.PubMedCrossRefGoogle Scholar
  34. 34.
    Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977;22:973–980.PubMedCrossRefGoogle Scholar
  35. 35.
    Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19:699–708.PubMedCrossRefGoogle Scholar
  36. 36.
    Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001;96:1587–1591.PubMedCrossRefGoogle Scholar
  37. 37.
    Parker DR, Kingham JG. Type I autoimmune hepatitis is primarily a disease of later life. QJM. 1997;90:289–296.PubMedCrossRefGoogle Scholar
  38. 38.
    Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008;25:219–239.PubMedCrossRefGoogle Scholar
  39. 39.
    McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet. 1990;335:754–757.PubMedCrossRefGoogle Scholar
  40. 40.
    Czaja AJ, Magrin S, Fabiano C, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci. 1995;40:33–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127–164.PubMedCrossRefGoogle Scholar
  42. 42.
    Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56:545–554.PubMedCrossRefGoogle Scholar
  43. 43.
    Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.PubMedCrossRefGoogle Scholar
  44. 44.
    Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.PubMedCrossRefGoogle Scholar
  45. 45.
    Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664–668.PubMedCrossRefGoogle Scholar
  46. 46.
    Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263–270.PubMedCrossRefGoogle Scholar
  47. 47.
    Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol. 2004;28:471–478.PubMedCrossRefGoogle Scholar
  48. 48.
    Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–249.PubMedCrossRefGoogle Scholar
  49. 49.
    Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol. 2007;38:1669–1675.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670–2673.PubMedCrossRefGoogle Scholar
  51. 51.
    Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr. 1990;116:280–282.PubMedCrossRefGoogle Scholar
  52. 52.
    Latif N, Mehmood K. Risk factors for fulminant hepatic failure and their relation with outcome in children. J Pak Med Assoc. 2010;60:175–178.PubMedGoogle Scholar
  53. 53.
    Della Corte C, Sartorelli MR, Sindoni CD, et al. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. Eur J Gastroenterol Hepatol. 2012;24:739–746.PubMedCrossRefGoogle Scholar
  54. 54.
    Potthoff A, Deterding K, Trautwein C, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007;45:15–19.PubMedCrossRefGoogle Scholar
  55. 55.
    Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–955.PubMedCrossRefGoogle Scholar
  56. 56.
    Nunez-Martinez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transpl Proc. 2003;35:1857–1858.CrossRefGoogle Scholar
  57. 57.
    Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33:36–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res. 2007;37:801–805.PubMedCrossRefGoogle Scholar
  59. 59.
    Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233–1235.PubMedGoogle Scholar
  60. 60.
    Graziadei IW. The clinical challenges of acute on chronic liver failure. Liver Int. 2011;31:24–26.PubMedCrossRefGoogle Scholar
  61. 61.
    Tanaka H, Tujioka H, Ueda H, et al. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol. 2005;11:6069–6071.PubMedGoogle Scholar
  62. 62.
    Huppertz HI, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204–208.PubMedCrossRefGoogle Scholar
  63. 63.
    Kerkar N, Hadzic N, Davies ET, et al. De novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409–413.PubMedCrossRefGoogle Scholar
  64. 64.
    Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci. 1989;34:1294–1297.PubMedCrossRefGoogle Scholar
  65. 65.
    Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation. 2004;78:128–135.PubMedCrossRefGoogle Scholar
  66. 66.
    Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183–1187.PubMedCrossRefGoogle Scholar
  67. 67.
    Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012;57:2248–2266.PubMedCrossRefGoogle Scholar
  68. 68.
    Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958.PubMedCrossRefGoogle Scholar
  69. 69.
    Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res. 2008;38:784–789.PubMedCrossRefGoogle Scholar
  70. 70.
    Miyake Y, Iwasaki Y, Kobashi H, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis. 2010;42:51–54.PubMedCrossRefGoogle Scholar
  71. 71.
    Czaja AJ. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci. 2012;57:610–624.PubMedCrossRefGoogle Scholar
  72. 72.
    Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622–627.PubMedCrossRefGoogle Scholar
  73. 73.
    Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848–857.PubMedCrossRefGoogle Scholar
  74. 74.
    Czaja AJ, Wolf AM, Baggenstoss AH. Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc. 1980;55:360–364.PubMedGoogle Scholar
  75. 75.
    Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol. 1998;161:3527–3535.PubMedGoogle Scholar
  76. 76.
    Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727–737.PubMedCrossRefGoogle Scholar
  77. 77.
    Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.PubMedCrossRefGoogle Scholar
  78. 78.
    De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol. 1988;48:290–296.PubMedCrossRefGoogle Scholar
  79. 79.
    Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr. 1990;10:71–96.PubMedGoogle Scholar
  80. 80.
    Currie MS. Immunosenescence. Compr Ther. 1992;18:26–34.PubMedGoogle Scholar
  81. 81.
    Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol. 1992;22:2989–2993.PubMedCrossRefGoogle Scholar
  82. 82.
    Ben-Yehuda A, Weksler ME. Immune senescence: mechanisms and clinical implications. Cancer Invest. 1992;10:525–531.PubMedCrossRefGoogle Scholar
  83. 83.
    Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–538.PubMedCrossRefGoogle Scholar
  84. 84.
    Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24–26.PubMedCrossRefGoogle Scholar
  85. 85.
    Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity. 1991;8:245–249.PubMedCrossRefGoogle Scholar
  86. 86.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502–1507.PubMedCrossRefGoogle Scholar
  87. 87.
    Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317–323.PubMedCrossRefGoogle Scholar
  88. 88.
    Bernal W, Ma Y, Smith HM, et al. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:664–670.PubMedCrossRefGoogle Scholar
  89. 89.
    Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46:1436–1442.PubMedCrossRefGoogle Scholar
  90. 90.
    Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.PubMedCrossRefGoogle Scholar
  91. 91.
    Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33–48.PubMedCrossRefGoogle Scholar
  92. 92.
    Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007;1:129–143.PubMedCrossRefGoogle Scholar
  93. 93.
    Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5:898–907.PubMedCrossRefGoogle Scholar
  94. 94.
    Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832.PubMedGoogle Scholar
  95. 95.
    Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26:459–466.PubMedCrossRefGoogle Scholar
  96. 96.
    Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–939.PubMedCrossRefGoogle Scholar
  97. 97.
    Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.PubMedCrossRefGoogle Scholar
  98. 98.
    Worns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008;103:138–146.PubMedCrossRefGoogle Scholar
  99. 99.
    Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int. 2012.Google Scholar
  100. 100.
    Lal J, Thapa BR, Rawal P, Ratho RK, Singh K. Predictors of outcome in acute-on-chronic liver failure in children. Hepatol Int. 2011;5:693–697.PubMedCrossRefGoogle Scholar
  101. 101.
    Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology. 2001;33:1512–1517.PubMedCrossRefGoogle Scholar
  102. 102.
    Grunhage F, Spengler U, Fischer HP, Sauerbruch T. Autoimmune hepatitis–sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion. 2004;70:187–191.PubMedCrossRefGoogle Scholar
  103. 103.
    Tabak F, Ozdemir F, Tabak O, et al. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Ann Hepatol. 2008;7:177–179.PubMedGoogle Scholar
  104. 104.
    Robertson DA, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet. 1987;2:9–11.PubMedCrossRefGoogle Scholar
  105. 105.
    Kalland KH, Endresen C, Haukenes G, Schrumpf E. Measles-specific nucleotide sequences and autoimmune chronic active hepatitis. Lancet. 1989;1:1390–1391.PubMedCrossRefGoogle Scholar
  106. 106.
    Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–2048.PubMedCrossRefGoogle Scholar
  107. 107.
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology. 1992;102:1406–1408.PubMedGoogle Scholar
  108. 108.
    Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 1992;116:51–53.PubMedGoogle Scholar
  109. 109.
    Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 1995;108:1770–1777.PubMedCrossRefGoogle Scholar
  110. 110.
    Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. 2011;43:666–667.PubMedCrossRefGoogle Scholar
  111. 111.
    Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85–90.PubMedCrossRefGoogle Scholar
  112. 112.
    Gossard AA, Lindor KD. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int. 2007;27:1086–1090.PubMedCrossRefGoogle Scholar
  113. 113.
    Montano-Loza AJ, Mason AL, Ma M, et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15:1254–1261.PubMedCrossRefGoogle Scholar
  114. 114.
    Czaja AJ. Recurrent autoimmune hepatitis after liver transplantation. Ann Gastroenterol Hepatol. 2010;1:79–89.Google Scholar
  115. 115.
    Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.PubMedCrossRefGoogle Scholar
  116. 116.
    Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55:965–967.PubMedCrossRefGoogle Scholar
  117. 117.
    Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–298.PubMedGoogle Scholar
  118. 118.
    O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–275.PubMedCrossRefGoogle Scholar
  119. 119.
    Tandon BN, Bernauau J, O’Grady J, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol. 1999;14:403–404.PubMedCrossRefGoogle Scholar
  120. 120.
    Wang Y, Chen Y, Gu C, Jiang L, Xiang D. Reevaluation of the nomenclature and diagnostic criteria in 477 patients with severe hepatitis. Zhonghua Gan Zang Bing Za Zhi. 2000;8:261–263.PubMedGoogle Scholar
  121. 121.
    Liu Q, Liu Z, Wang T, et al. Characteristics of acute and sub-acute liver failure in China: nomination, classification and interval. J Gastroenterol Hepatol. 2007;22:2101–2106.PubMedCrossRefGoogle Scholar
  122. 122.
    Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805–812.PubMedCrossRefGoogle Scholar
  123. 123.
    Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998–1005.PubMedCrossRefGoogle Scholar
  124. 124.
    Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. The Study Group of Fulminant Hepatitis. J Gastroenterol Hepatol. 1991;6:159–164.PubMedCrossRefGoogle Scholar
  125. 125.
    Gimson AE, O’Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology. 1986;6:288–294.PubMedCrossRefGoogle Scholar
  126. 126.
    Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986;6:97–106.PubMedCrossRefGoogle Scholar
  127. 127.
    Tandon BN, Joshi YK, Krishnamurthy L, Tandon HD. Subacute hepatic failure; is it a distinct entity? J Clin Gastroenterol. 1982;4:343–346.Google Scholar
  128. 128.
    Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. Systematic review: acute liver failure—one disease, more than 40 definitions. Aliment Pharmacol Ther. 2012;35:1245–1256.PubMedCrossRefGoogle Scholar
  129. 129.
    Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int. 2011;31:1013–1020.PubMedCrossRefGoogle Scholar
  130. 130.
    Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. J Pediatr Gastroenterol Nutr. 2005;40:575–581.PubMedCrossRefGoogle Scholar
  131. 131.
    Hiramatsu A, Takahashi S, Aikata H, et al. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol. 2008;23:1216–1222.PubMedCrossRefGoogle Scholar
  132. 132.
    Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6:163–169.PubMedGoogle Scholar
  133. 133.
    Narkewicz MR, Dell Olio D, Karpen SJ, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr. 2009;155:801–806.PubMedCrossRefGoogle Scholar
  134. 134.
    Ikegami T, Taketomi A, Soejima Y, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg. 2008;206:412–418.PubMedCrossRefGoogle Scholar
  135. 135.
    Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421–3438.PubMedCrossRefGoogle Scholar
  136. 136.
    Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–1548.PubMedCrossRefGoogle Scholar
  137. 137.
    O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–445.PubMedGoogle Scholar
  138. 138.
    Sahni VA, Raghunathan G, Mearadji B, et al. Autoimmune hepatitis: CT and MR imaging features with histopathological correlation. Abdom Imaging. 2010;35:75–84.PubMedCrossRefGoogle Scholar
  139. 139.
    Cakir B, Kirbas I, Demirhan B, et al. Fulminant hepatic failure in children: etiology, histopathology and MDCT findings. Eur J Radiol. 2009;72:327–334.PubMedCrossRefGoogle Scholar
  140. 140.
    Yasui S, Fujiwara K, Okitsu K, et al. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res. 2012;42:42–50.PubMedCrossRefGoogle Scholar
  141. 141.
    Heringlake S, Schutte A, Flemming P, et al. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47:417–423.PubMedCrossRefGoogle Scholar
  142. 142.
    Wehbe AM, Johannsson B, Raife TJ, et al. Severe autoimmune neutropenia associated with acute autoimmune hepatitis. Int J Hematol. 2010;91:673–678.PubMedCrossRefGoogle Scholar
  143. 143.
    Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res. 2001;21:213–219.PubMedCrossRefGoogle Scholar
  144. 144.
    Kage M. Pathology of autoimmune liver diseases in children. Hepatol Res. 2007;37:S502–S508.PubMedCrossRefGoogle Scholar
  145. 145.
    Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol. 2007;5:255–258.PubMedCrossRefGoogle Scholar
  146. 146.
    Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50:538–545.PubMedCrossRefGoogle Scholar
  147. 147.
    Murakami T, Baron RL, Peterson MS. Liver necrosis and regeneration after fulminant hepatitis: pathologic correlation with CT and MR findings. Radiology. 1996;198:239–242.PubMedGoogle Scholar
  148. 148.
    Qayyum A, Graser A, Westphalen A, et al. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR. 2004;183:1573–1576.PubMedCrossRefGoogle Scholar
  149. 149.
    Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250–259.PubMedCrossRefGoogle Scholar
  150. 150.
    Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.PubMedCrossRefGoogle Scholar
  151. 151.
    Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402–2407.PubMedCrossRefGoogle Scholar
  152. 152.
    Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302–308.PubMedCrossRefGoogle Scholar
  153. 153.
    Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146–150.PubMedCrossRefGoogle Scholar
  154. 154.
    Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol. 2001;62:165–169.PubMedCrossRefGoogle Scholar
  155. 155.
    Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology. 1990;12:1300–1304.PubMedCrossRefGoogle Scholar
  156. 156.
    Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology. 1992;103:1041–1047.PubMedGoogle Scholar
  157. 157.
    Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31:49–53.PubMedCrossRefGoogle Scholar
  158. 158.
    Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851–856.PubMedCrossRefGoogle Scholar
  159. 159.
    Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645–652.PubMedCrossRefGoogle Scholar
  160. 160.
    Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322–1329.PubMedCrossRefGoogle Scholar
  161. 161.
    Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227–235.PubMedCrossRefGoogle Scholar
  162. 162.
    Yokosawa S, Yoshizawa K, Ota M, et al. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology. 2007;45:384–390.PubMedCrossRefGoogle Scholar
  163. 163.
    Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute-onset autoimmune hepatitis. Histopathology. 2011;58:693–704.PubMedCrossRefGoogle Scholar
  164. 164.
    Warren A, Bertolino P, Benseler V, et al. Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. J Hepatol. 2007;46:239–246.PubMedCrossRefGoogle Scholar
  165. 165.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138–1145.PubMedCrossRefGoogle Scholar
  166. 166.
    Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut. 2008;57:252–257.PubMedCrossRefGoogle Scholar
  167. 167.
    Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53:926–934.PubMedCrossRefGoogle Scholar
  168. 168.
    Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448–453.PubMedGoogle Scholar
  169. 169.
    Kumar R, Shalimar, Sharma H, et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut. 2012;61:1068–1075.Google Scholar
  170. 170.
    Naiki T, Nakayama N, Mochida S, et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: application to indication criteria for liver transplantation. Hepatol Res. 2012;42:68–75.PubMedCrossRefGoogle Scholar
  171. 171.
    Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–1206.PubMedCrossRefGoogle Scholar
  172. 172.
    Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987;93:890–893.PubMedGoogle Scholar
  173. 173.
    Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17:317–320.PubMedCrossRefGoogle Scholar
  174. 174.
    Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040–1047.PubMedCrossRefGoogle Scholar
  175. 175.
    Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36:459–461.PubMedCrossRefGoogle Scholar
  176. 176.
    Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241–248.PubMedCrossRefGoogle Scholar
  177. 177.
    Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321–1327.PubMedCrossRefGoogle Scholar
  178. 178.
    Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771–776.PubMedGoogle Scholar
  179. 179.
    Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805–809.PubMedCrossRefGoogle Scholar
  180. 180.
    Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232–3236.PubMedGoogle Scholar
  181. 181.
    Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405–407.PubMedCrossRefGoogle Scholar
  182. 182.
    Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063–3070.PubMedCrossRefGoogle Scholar
  183. 183.
    Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588–592.PubMedGoogle Scholar
  184. 184.
    Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335–343.PubMedCrossRefGoogle Scholar
  185. 185.
    Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012;57:1996–2010.PubMedCrossRefGoogle Scholar
  186. 186.
    Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-I. Inflamm Allergy Drug Targets. 2012;11:337–350.Google Scholar
  187. 187.
    Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215–221.PubMedCrossRefGoogle Scholar
  188. 188.
    Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18:62–69.PubMedCrossRefGoogle Scholar
  189. 189.
    Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007;13:1382–1388.PubMedCrossRefGoogle Scholar
  190. 190.
    Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876–883.PubMedCrossRefGoogle Scholar
  191. 191.
    Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319–333.PubMedCrossRefGoogle Scholar
  192. 192.
    Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.PubMedCrossRefGoogle Scholar
  193. 193.
    Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976;8:221–227.PubMedGoogle Scholar
  194. 194.
    Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des. 2011;17:3120–3140.PubMedCrossRefGoogle Scholar
  195. 195.
    Czaja AJ. Drug choices in autoimmune hepatitis: Part B—non-steroids. Expert Rev Gastroenterol Hepatol. 2012;6:617–635.Google Scholar
  196. 196.
    Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691–707.Google Scholar
  197. 197.
    Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol. 2012;26:615–620.Google Scholar
  198. 198.
    Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819–825.PubMedCrossRefGoogle Scholar
  199. 199.
    Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371–375.PubMedCrossRefGoogle Scholar
  200. 200.
    Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8–10.PubMedCrossRefGoogle Scholar
  201. 201.
    Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119:1312–1316.PubMedCrossRefGoogle Scholar
  202. 202.
    Czaja AJ. Drug choices in autoimmune hepatitis: Part A—steroids. Expert Rev Gastroenterol Hepatol. 2012;6:603–615.Google Scholar
  203. 203.
    Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63–83.PubMedCrossRefGoogle Scholar
  204. 204.
    Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61–98.PubMedCrossRefGoogle Scholar
  205. 205.
    Schalm SW, Summerskill WH, Go VL. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology. 1977;72:910–913.PubMedGoogle Scholar
  206. 206.
    Uribe M, Schalm SW, Summerskill WH, Go VL. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut. 1978;19:1131–1135.PubMedCrossRefGoogle Scholar
  207. 207.
    Uribe M, Go VL. Corticosteroid pharmacokinetics in liver disease. Clin Pharmacokinet. 1979;4:233–240.PubMedCrossRefGoogle Scholar
  208. 208.
    Uribe M, Summerskill WH, Go VL. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin Pharmacokinet. 1982;7:452–459.PubMedCrossRefGoogle Scholar
  209. 209.
    Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos. 1994;15:163–172.PubMedCrossRefGoogle Scholar
  210. 210.
    Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets. 2012;11:351–363.Google Scholar
  211. 211.
    Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712–2726.PubMedCrossRefGoogle Scholar
  212. 212.
    Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transpl Proc. 2007;39:1166–1170.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations